Vanguard Global Advisers
NVCR icon

Vanguard Global Advisers’s NovoCure NVCR Stock Holding History

Vanguard Global Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Sell
39,700
-2,061
-5% -$31.2K ﹤0.01% 2020
2026
Q1 		$455K Buy
+41,761
New +$522K ﹤0.01% 2090

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Global Advisers's NVCR Position: Q2 2026 in Review

Vanguard Global Advisers reduced its NovoCure (NVCR) stake by 4.9% in Q2 2026, selling an estimated $31.2K and leaving 39,700 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #2020.

Vanguard Global Advisers first reported a position in NVCR in Q1 2026 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Vanguard Global Advisers held 39,700 shares of NovoCure worth $601K as of Q2 2026.
  • Vanguard Global Advisers sold 2,061 NovoCure shares in Q2 2026, an estimated $31.2K.
  • NovoCure made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2020 holding.
  • Vanguard Global Advisers first reported a position in NovoCure in Q1 2026 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.